A Tony Coles Parkin­son's biotech, Yu­man­i­ty, con­tin­ues its back­slide as lead pro­gram earns a par­tial hold

A Tony Coles biotech look­ing to de­vel­op new drugs for Parkin­son’s dis­ease and oth­er neu­ro­log­i­cal con­di­tions ran in­to trou­ble Wednes­day as the FDA slapped its lead pro­gram with a par­tial clin­i­cal hold.

Yu­man­i­ty will need to pause stud­ies eval­u­at­ing mul­ti-dose ad­min­is­tra­tion of the drug, dubbed YTX-7739, in Parkin­son’s, the biotech said. Though Yu­man­i­ty did not elab­o­rate on what ex­act­ly reg­u­la­tors took is­sue with, the FDA is al­low­ing a planned study of a sin­gle dose to go ahead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER